Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIIIW) Liabilities and Shareholders Equity (2020 - 2025)

P3 Health Partners' Liabilities and Shareholders Equity history spans 6 years, with the latest figure at $656.6 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 16.18% year-over-year to $656.6 million; the TTM value through Dec 2025 reached $2.9 billion, down 15.15%, while the annual FY2025 figure was $656.6 million, 16.18% down from the prior year.
  • Liabilities and Shareholders Equity reached $656.6 million in Q4 2025 per PIIIW's latest filing, down from $683.6 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.4 billion in Q1 2022 to a low of $94.2 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $870.7 million, with a median of $855.9 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 2402.01% in 2022, then tumbled 63.19% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $316.6 million in 2021, then soared by 176.85% to $876.6 million in 2022, then decreased by 1.78% to $861.0 million in 2023, then decreased by 9.01% to $783.4 million in 2024, then decreased by 16.18% to $656.6 million in 2025.
  • Per Business Quant, the three most recent readings for PIIIW's Liabilities and Shareholders Equity are $656.6 million (Q4 2025), $683.6 million (Q3 2025), and $731.6 million (Q2 2025).